American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease

      This document presents the official recommendations of the American Gastroenterological Association (AGA) on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD). The guideline was developed by the AGA’s Clinical Guidelines Committee and approved by the AGA Governing Board. It is accompanied by a Technical Review, which is a compilation of clinical evidence from which these recommendations were formulated.
      • Vande Casteele N.
      • Herfarth H.
      • Katz J.
      • et al.
      American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases.

      Abbreviations used in this paper:

      AGA (American Gastroenterological Association), CBC (complete blood count), CI (confidence interval), GRADE (Grading of Recommendations Assessment, Development and Evaluation), IBD (inflammatory bowel disease), RCT (randomized controlled trial), RR (relative risk), TDM (therapeutic drug monitoring), 6-TGN (6-thioguanine), TNF (tumor necrosis factor), TPMT (thiopurine methyltransferase)
      To read this article in full you will need to make a payment
      AGA Member Login
      Login with your AGA username and password.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Vande Casteele N.
        • Herfarth H.
        • Katz J.
        • et al.
        American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases.
        Gastroenterology. 2017; 153: 835-857
        • Colombel J.F.
        • Narula N.
        • Peyrin-Biroulet L.
        Management strategies to improve outcomes of patients with inflammatory bowel diseases.
        Gastroenterology. 2017; 152: 351-361 e5
        • European Medicines Agency
        Guideline on Bioanalytical Method Validation.
        European Medicine Agency, London2009
        • US Food and Drug Administration
        Guidance for Industry: Bioanalytical Method Validation.
        US Food and Drug Administration, Silver Springs, MD2013
        • Bodini G.
        • Giannini E.G.
        • Furnari M.
        • et al.
        Comparison of two different techniques to assess adalimumab trough levels in patients with Crohn's disease.
        J Gastrointestin Liver Dis. 2015; 24: 451-456
        • Graham R.
        • Mancher M.
        • Wolman D.M.
        • et al.
        Clinical Practice Guidelines We Can Trust.
        National Academies Press, Washinton, DC2011
        • Sultan S.
        • Falck-Ytter Y.
        • Inadomi J.M.
        The AGA institute process for developing clinical practice guidelines part one: grading the evidence.
        Clin Gastroenterol Hepatol. 2013; 11: 329-332
        • Steenholdt C.
        • Brynskov J.
        • Thomsen O.
        • et al.
        Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
        Gut. Volume. 2014; 63: 919-927
        • Paul S.
        • Del Tedesco E.
        • Marotte H.
        • et al.
        Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
        Inflamm Bowel Dis. 2013; 19: 2568-2576
        • Roblin X.
        • Marotte H.
        • Rinaudo M.
        • et al.
        Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.
        Clin Gastroenterol Hepatol. 2014; 12: 80-84.e2
        • Yanai H.
        • Lichtenstein L.
        • Assa A.
        • et al.
        Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
        Clin Gastroenterol Hepatol. 2015; 13: 522-530
        • Ungar B.
        • Levy I.
        • Yavne Y.
        • et al.
        Optimizing anti-TNF-α therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases.
        Clin Gastroenterol Hepatol. 2016; 14: 550-557.e2
        • Adedokun O.J.
        • Sandborn W.J.
        • Feagan B.G.
        • et al.
        Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis.
        Gastroenterology. 2014; 147: 1296-1307.e5
        • Reinisch W.
        • Colombel J.F.
        • Sandborn W.J.
        • et al.
        Factors associated with short- and long-term outcomes of therapy for crohn's disease.
        Clin Gastroenterol Hepatol. 2015; 13: 539-547
        • Arias M.T.
        • Vande Casteele N.
        • Vermeire S.
        • et al.
        A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.
        Clin Gastroenterol Hepatol. 2015; 13: 531-538
        • Bortlik M.
        • Duricova D.
        • Malickova K.
        • et al.
        Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.
        J Crohns Colitis. 2013; 7: 736-743
        • Singh N.
        • Rosenthal C.J.
        • Melmed G.Y.
        • et al.
        Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease.
        Inflamm Bowel Dis. 2014; 20: 1708-1713
        • Warman A.
        • Straathof J.W.A.
        • Derijks L.J.J.
        Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
        Eur J Gastroenterol Hepatol. 2015; 27: 242-248
        • Chaparro M.
        • Guerra I.
        • Iborra M.
        • et al.
        Correlation between adalimumab serum levels and remission after the induction phase in crohn's disease patients.
        Gastroenterology. 2015; 148: S107-S108
        • Frederiksen M.T.
        • Ainsworth M.A.
        • Brynskov J.
        • et al.
        Antibodies against infliximab (IFX) are associated with de novo development of antibodies to adalimumab (ADL) and therapeutic failure in IFX-to-ADL switchers with inflammatory bowel disease.
        Inflamm Bowel Dis. 2014; 20: 1714-1721
        • Mazor Y.
        • Almog R.
        • Kopylov U.
        • et al.
        Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.
        Aliment Pharmacol Ther. 2014; 40: 620-628
        • Steenholdt C.
        • Bendtzen K.
        • Brynskov J.
        • et al.
        Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post-hoc analysis of a randomized controlled trial.
        Am J Gastroenterol. 2014; 109: 1055-1064
        • Ward M.G.
        • Kariyawasam V.C.
        • Mogan S.B.
        • et al.
        Clinical utility of measuring adalimumab trough levels and antibodies to adalimumab in patients with inflammatory bowel diseases.
        J Gastroenterol Hepatol. 2013; 28: 100-101
        • Vande Casteele N.
        • Ferrante M.
        • Van Assche G.
        • et al.
        Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
        Gastroenterology. 2015; 148: 1320-1329
        • Vaughn B.P.
        • Martinez-Vazquez M.
        • Patwardhan V.R.
        • et al.
        Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study.
        Inflamm Bowel Dis. 2014; 20: 1996-2003
        • Coenen M.J.H.
        • De Jong D.J.
        • Van Marrewijk C.J.
        • et al.
        Identification of patients with variants in TPMT and dose reduction reduces hematologic events during thiopurine treatment of inflammatory bowel disease.
        Gastroenterology. 2015; 149: 907-917
        • Newman W.G.
        • Payne K.
        • Tricker K.
        • et al.
        A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.
        Pharmacogenomics. 2011; 12: 815-826
        • Sayani F.A.
        • Prosser C.
        • Bailey R.J.
        • et al.
        Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events.
        Can J Gastroenterol. 2005; 19: 147-151
        • Lewis J.D.
        • Abramson O.
        • Pascua M.
        • et al.
        Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations.
        Clin Gastroenterol Hepatol. 2009; 7: 1195-1201
        • Haines M.L.
        • Ajlouni Y.
        • Irving P.M.
        • et al.
        Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
        Inflamm Bowel Dis. 2011; 17: 1301-1307
        • Reinshagen M.
        • Schütz E.
        • Armstrong V.W.
        • et al.
        6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
        Clin Chem. 2007; 53: 1306-1314
        • Van Asseldonk D.P.
        • Sanderson J.
        • de Boer N.K.H.
        • et al.
        Difficulties and possibilities with thiopurine therapy in inflammatory bowel disease—proceedings of the first Thiopurine Task Force meeting.
        Digest Liver Dis. 2011; 43: 270-276
        • American Gastroenterological Association
        Therapeutic drug monitoring in inflammatory bowel disease––clinical decision support tool.
        Gastroenterology. 2017; 153: 858-859

      Linked Article